CCM
LEGN icon

CAAS Capital Management’s Legend Biotech LEGN Stock Holding History

CAAS Capital Management’s Portfolio LEGN Stock Details LEGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-46,334
Closed -$2.16M – 813
2021
Q4 		$2.16M Buy
+46,334
New +$2.35M 0.05% 306
2020
Q3 		– Sell
-80,000
Closed -$3.4M – 550
2020
Q2 		$3.4M Buy
+80,000
New +$3.13M 0.11% 171

Other funds holding LEGN

HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

CAAS Capital Management's LEGN Position: Q1 2022 in Review

CAAS Capital Management sold out of Legend Biotech (LEGN) in Q1 2022, closing a stake of 46,334 shares — an estimated $2.16M sold.

CAAS Capital Management first reported a position in LEGN in Q2 2020 and held it in 2 quarters. The position peaked at $3.4M in Q2 2020. 141 funds tracked by Wall St. Rank hold LEGN as of Q1 2022.

  • CAAS Capital Management reported no remaining Legend Biotech position as of Q1 2022 after selling out during the quarter.
  • CAAS Capital Management sold 46,334 Legend Biotech shares in Q1 2022, an estimated $2.16M.
  • CAAS Capital Management first reported a position in Legend Biotech in Q2 2020 and held it in 2 quarters.
  • CAAS Capital Management's Legend Biotech position peaked at $3.4M in Q2 2020.
  • 141 funds tracked by Wall St. Rank held Legend Biotech as of Q1 2022.

Based on CAAS Capital Management's 13F filing for Q1 2022, filed 13 May 2022.